Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia


The purpose of this study is to investigate the safety of a test drug to treat hemophilia in adult men.

Full Title of Study: “A Multicenter, Non-randomized, Open-label, Multiple Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous BAY1093884 in Males With Severe Hemophilia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 29, 2020

Detailed Description

The primary objective is to assess the safety of multiple doses of BAY1093884.


  • Drug: BAY1093884
    • Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)

Arms, Groups and Cohorts

  • Experimental: Hemophilia
    • Dose escalation starting with 200 mg of BAY1093884

Clinical Trial Outcome Measures

Primary Measures

  • Frequency of drug-related adverse events
    • Time Frame: Up to 3 months
  • Frequency of drug-related serious adverse events
    • Time Frame: Up to 3 months
  • Frequency of adverse events of special interest
    • Time Frame: Up to 3 months
    • Adverse events of special interest comprise thromboembolic and thrombotic microangiopathy events, and hypersensitivity reactions.

Participating in This Clinical Trial

Inclusion Criteria

  • Participants with hemophilia A and FVIII activity <1% or hemophilia B with FIX activity <2% – Participants must be currently without inhibitors or with low titer inhibitors (inhibitor titer < 5 Bethesda units) who are receiving current on demand treatment with any FVIII or FIX (recombinant or plasma-derived; modified or unmodified) Exclusion Criteria:
  • History or at risk of developing diseases related to venous thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis or thrombophlebitis) – History of any other clinically relevant coagulation disorder (particularly disseminated intravascular coagulopathy or combined FVIII/Factor V deficiency) or platelet disorder – History or at risk of developing cardiac, coronary and/or arterial peripheral atherosclerotic disease and/or arterial thromboembolic events, particularly myocardial infarction, cerebrovascular accident, stroke, transient ischemic attack, congestive heart failure, angina pectoris, treatment for angina pectoris or uncontrolled hypertension – History or at risk for thrombotic microangiopathy
  • Gender Eligibility: Male

    Minimum Age: 18 Years

    Maximum Age: 65 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Bayer
    • Provider of Information About this Clinical Study
      • Sponsor

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.